Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.
about
Duration of antimicrobial therapy in community acquired pneumonia: less is morePharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh modelTelithromycin: a novel agent for the treatment of community-acquired upper respiratory infectionsKetolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.Telithromycin: an oral ketolide for respiratory infections.Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages.Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infectionsQuantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophagesFluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials.Controlled trial of a 5-day course of telithromycin versus doxycycline for treatment of mild to moderate scrub typhusTelithromycin in lower respiratory tract infections.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumoniaPharmacokinetics of EDP-420 after ascending single oral doses in healthy adult volunteers.Qualitative structure-metabolism relationships in the hydrolysis of carbamates.Recent advances in antibacterial drugs.Ketolides in the treatment of community-acquired respiratory tract infections: A review.Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor.Inhibition of secretion of interleukin-1alpha and tumor necrosis factor alpha by the ketolide antibiotic telithromycin.Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycinPharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers.Telithromycin and quinupristin-dalfopristin induce delayed death in Plasmodium falciparum.Antibiotic resistance: where do ketolides fit?Lack of effect of food on the bioavailability of a new ketolide antibacterial, telithromycin.Oral telithromycin 800 mg once daily for 5 days versus cefuroxime axetil 500 mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis.Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment.Efficacy and safety of oral telithromycin once daily for 5 days versus moxifloxacin once daily for 10 days in the treatment of acute bacterial rhinosinusitis.Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin.The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole.
P2860
Q26828493-C278F618-3F61-4730-B7D7-456C2FF7FA84Q33555366-A556C3B0-4E5B-45BB-9C86-AC092AE52A15Q33945038-9DB7A296-30AD-4677-8C52-0A098DF8245AQ34281970-8BCC92F3-CE9C-4457-BC6E-3A489435AB20Q34401542-41D4BAD5-506B-4AE5-9826-84977C040226Q34509728-34DE9646-3D9C-490C-9ACC-4202FB0479FBQ35102381-0A17BEEF-CDAF-4C52-B89A-A3E770D5FDC3Q35102754-3AD124C0-BDF8-4864-BA21-9374F2E6D5D5Q35547236-490F9A61-13B6-4260-9F99-A99C1F66D2A3Q35840827-9AF98F82-4EEF-49F2-BBA6-69D93DD6C952Q36895727-FD2E4612-9183-4D03-9344-4E00BAF321C7Q37116814-9BAA3CAD-2A64-419B-A93D-56B7270521F6Q37190854-B4F4AB43-8D66-4C1E-9E0C-4225896523FFQ37742109-E453F3BC-73A4-4C05-8E65-F89944A0E5DBQ38115306-3CA3A8EA-ABDC-488C-8265-9C3760C6F38CQ38199663-A589D3FE-4148-49D0-A98B-0E01C2AEEED2Q39643626-68320FD3-C821-424B-A837-74CD2EAA9C80Q39658071-80FFE8DF-7017-4A97-B04D-616EEC9AB10DQ40417004-FE8A2904-4FEA-4112-8A9C-67B1D29A9C01Q40425618-6EC46632-D75A-4039-BFA2-1AA084E7626BQ41915221-5697D925-8B8D-4B76-BED4-04B3D0F2606CQ43595556-91C41DB9-D4C5-4139-8A5A-1A3A634882F0Q44309655-D6A4EE8D-870A-41DF-A78A-1AA8BA69ECE9Q44518070-D15A01C7-217E-45E3-BFAC-DCDD66FE524CQ44770176-6340346E-D89A-46E3-B390-9C31104DC16DQ45057564-ACC5AA64-CF44-4F4A-BFBB-3409E72C70CCQ46378358-E21BBF8C-9BAE-4012-9FD6-73D13CD4917BQ46650427-8D182AD9-26E1-4C6D-867F-0519F5F2FCD7
P2860
Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@ast
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@en
type
label
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@ast
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@en
prefLabel
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@ast
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@en
P2093
P2860
P1476
Pharmacokinetics of the new ke ...... ing single and multiple doses.
@en
P2093
P2860
P304
P356
10.1128/AAC.45.1.170-175.2001
P407
P577
2001-01-01T00:00:00Z